TOP TEN perturbations for 39378_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39378_at
Selected probe(set): 208946_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39378_at (208946_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.9215317
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-1.8418121
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer┬┤s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.7729712
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)

Relative Expression (log2-ratio):-1.7205057
Number of Samples:12 / 20
Experimental endometriosis study 6 (minimal/mild endo.; pro. MCP)
Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control normal endometrium tissue (pro. MCP)
Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-1.7169714
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)

Relative Expression (log2-ratio):1.7160721
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (inflammatory carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.6654186
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):1.6084328
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)

Relative Expression (log2-ratio):-1.5746565
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.

expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (mucinous adenocarcinoma; primary)

Relative Expression (log2-ratio):-1.5072432
Number of Samples:2 / 6
Experimental expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS).
Control expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma.